Exelixis Inc., South San Francisco, and Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, have signed an exclusive licensing agreement for the commercialization and further clinical development in Japan of cabozantinib, Exelixis' lead oncology medicine.